{"id":"W3080988574","doi":"10.1200/jco.20.01164","title":"MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Cycle for Survival; Ovarian Cancer Research Fund Alliance; Array BioPharma; Memorial Sloan-Kettering Cancer Center; Pfizer; Ovarian Cancer Research Fund","keywords":"Medicine; Hazard ratio; Chemotherapy; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; KRAS; Serous fluid; Chemotherapy regimen; Surgery; Gastroenterology; Randomized controlled trial; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008180338,0.0002611388,0.001972653,0.00008152871,0.00004388628,0.000009649157,0.0003630872,0.0003079555,0.0001805168],"category_scores_gemma":[0.001255953,0.000140746,0.001078052,0.0004037179,0.0002452587,0.00007573921,0.00009510497,0.00111449,0.00000723016],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005000365,"about_ca_system_score_gemma":0.002835186,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000828408,"about_ca_topic_score_gemma":0.0001942627,"domain_scores_codex":[0.9960539,0.0005094045,0.002202436,0.0003602712,0.0005457086,0.0003282793],"domain_scores_gemma":[0.9953664,0.002226189,0.001424441,0.0003308763,0.0002330586,0.0004190352],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1522071,0.02596316,0.3774196,0.00081053,0.00469137,0.001929794,0.003422043,0.00009508113,0.0008405749,0.0000726881,0.03386511,0.398683],"study_design_scores_gemma":[0.04167304,0.04478338,0.7243214,0.0005100238,0.0008958213,0.00009956567,0.0005102492,0.0001148721,0.0004579407,0.00000658654,0.1864373,0.0001897938],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9098423,0.001729369,0.00000163141,0.08438636,0.002307786,0.0005623753,0.00001454745,0.000008964027,0.001146627],"genre_scores_gemma":[0.977129,0.004520861,0.000881414,0.01492036,0.002346603,0.0000185353,0.000003845775,0.00003852411,0.0001407833],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3984932,"threshold_uncertainty_score":0.5739457,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1873591823960311,"score_gpt":0.4321359889363601,"score_spread":0.244776806540329,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}